Cardiac Peroxisome Proliferator-Activated Receptor δ (PPARδ) as a New Target for Increased Contractility without Altering Heart Rate

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Chen, Zhih Cherng ^a,e   Lee, Kung Shing ^b   Chen, Li Jen ^c   Wang, Lin Yu ^a   Niu, Ho Shan ^d   Cheng, Juei Tang ^a,c  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

^e CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4 ANILINO 2 METHOXYPHENYL)SULFAMOYL] 2 THENOIC ACID METHYL ESTER; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; CALCIUM; DOBUTAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; TROPONIN I;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CALCIUM CELL LEVEL; CONTROLLED STUDY; HEART FAILURE; HEART HEMODYNAMICS; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART PERFORMANCE; HEART RATE; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NEWBORN; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN PHOSPHORYLATION; QRS COMPLEX; RAT; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANESTHESIA; ANIMALS; ANIMALS, NEWBORN; BLOOD PRESSURE; CALCIUM; DIABETES MELLITUS, EXPERIMENTAL; DOBUTAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; INTRACELLULAR SPACE; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHORYLATION; PPAR DELTA; RATS; RATS, WISTAR; STREPTOZOCIN; THIAZOLES; TROPONIN I;

RATTUS;

EID: 84878404310     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064229     Document Type: Article

References (57)

1. Antman EM, Smith TW, (1989) Current concepts in the use of digitalis. Adv Intern Med 34: 425-454.
2. Zaugg CE, (2004) Current concepts on ventricular fibrillation: a vicious circle of cardiomyocyte calcium overload in the initiation, maintenance, and termination of ventricular fibrillation. Indian Pacing Electrophysiol J 4: 85-92.
3. Hjemdahl P, (1993) Plasma catecholamines-analytical challenges and physiological limitations. Baillieres Clin Endocrinol Metab 7: 307-353.
4. Iino K, Ito H, (2007) [Catecholamines use in patients with heart failure]. Nihon Rinsho 65Suppl 5: 30-33.
5. Kagaya Y, (2007) [Catecholamines-characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects]. Nihon Rinsho 65Suppl 5: 25-29.
6. Ahmed I, House CM, Nelson WB, (2009) Predictors of inotrope use in patients undergoing concomitant coronary artery bypass graft (CABG) and aortic valve replacement (AVR) surgeries at separation from cardiopulmonary bypass (CPB). J Cardiothorac Surg 4: 24.
7. Dani C, Vestri V, Bertini G, Pratesi S, Rubaltelli FF, (2007) Toxicity of corticosteroids and catecholamines for mice neuronal cell cultures: Role of preservatives. J Matern Fetal Neonatal Med 20: 325-333.
8. Leone M, Martin C, (2008) Vasopressor use in septic shock: an update. Curr Opin Anaesthesiol 21: 141-147.
9. Editor (2011) Vassopressors and inotropes. Med Lett Drugs Ther 53: 90-92.
10. Alousi AA, Farah AE, Lesher GY, Opalka CJ Jr, (1979) Cardiotonic activity of amrinone-Win 40680 [5-amino-3,4'-bipyridine-6(1H)-one]. Circ Res 45: 666-677.
11. Katz AM, McCall D, Messineo FC, Pappano A, Dobbs W, (1980) Comments on "cardiotonic activity of amrinone-win 40680 [5-amino-3-4'-bypyridin-6(1H)-one]". Circ Res 46: 887-888.
12. Yang Q, Li Y, (2007) Roles of PPARs on regulating myocardial energy and lipid homeostasis. J Mol Med 85: 697-706.
13. Issemann I, Green S, (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650.
14. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, et al. (2004) Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 10: 1245-1250.
15. Cheng L, Ding G, Qin Q, Xiao Y, Woods D, et al. (2004) Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes. Biochem Biophys Res Commun 313: 277-286.
16. Barish GD, Narkar VA, Evans RM, (2006) PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 116: 590-597.
17. Chou MT, Lo SH, Cheng KC, Li YX, Chen LJ, et al. (2012) Activation of beta-adrenoceptors by dobutamine may induce a higher expression of peroxisome proliferator-activated receptors delta (PPARdelta) in neonatal rat cardiomyocytes. ScientificWorldJournal 2012: 248320.
18. Chen ZC, Yu BC, Chen LJ, Cheng KC, Lin HJ, et al. (2011) Characterization of the mechanisms of the increase in PPARdelta expression induced by digoxin in the heart using the H9c2 cell line. Br J Pharmacol 163: 390-398.
19. Chen ZC, Yu BC, Chen LJ, Cheng JT (2012) Increase of Peroxisome Proliferator-activated Receptor delta (PPARdelta) by Digoxin to Improve Lipid Metabolism in the Heart of Diabetic Rats. Horm Metab Res.
20. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, et al. (2003) Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)-synthesis and biological activity. Bioorg Med Chem Lett 13: 1517-1521.
21. Bility MT, Devlin-Durante MK, Blazanin N, Glick AB, Ward JM, et al. (2008) Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis. Carcinogenesis 29: 2406-2414.
22. Gaudel C, Schwartz C, Giordano C, Abumrad NA, Grimaldi PA, (2008) Pharmacological activation of PPARbeta promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle. Am J Physiol Endocrinol Metab 295: E297-304.
23. Wagner N, Jehl-Pietri C, Lopez P, Murdaca J, Giordano C, et al. (2009) Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin. Cardiovasc Res 83: 61-71.
24. Cheng JT, Huang CC, Liu IM, Tzeng TF, Chang CJ, (2006) Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats. Diabetes 55: 819-825.
25. Sun L, Li DL, Zhao M, He X, Yu XJ, et al. (2011) The Role of Muscarinic Receptors in the Beneficial Effects of Adenosine against Myocardial Reperfusion Injury in Rats. PLoS One 6: e25618.
26. Seldinger SI, (2008) Catheter replacement of the needle in percutaneous arteriography. A new technique. Acta Radiol Suppl (Stockholm) 434: 47-52.
27. Schneyer CA, (1986) Growth of rat salivary glands after terbutaline or dobutamine. J Oral Pathol 15: 66-70.
28. Wu JY, Liaw WJ, Tzao C, Chen SJ, Wang JH, et al. (2002) Comparison of terbutaline and dobutamine in rats with endotoxemia. Chin J Physiol 45: 155-162.
29. Zarzuelo MJ, Jimenez R, Galindo P, Sanchez M, Nieto A, et al. (2011) Antihypertensive effects of peroxisome proliferator-activated receptor-beta activation in spontaneously hypertensive rats. Hypertension 58: 733-743.
30. Paterniti I, Esposito E, Mazzon E, Galuppo M, Di Paola R, et al. (2010) Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury. J Pharmacol Exp Ther 333: 465-477.
31. Cohen G, Riahi Y, Shamni O, Guichardant M, Chatgilialoglu C, et al. (2011) Role of lipid peroxidation and PPAR-delta in amplifying glucose-stimulated insulin secretion. Diabetes 60: 2830-2842.
32. Hallaq HA, Haupert GT Jr, (1989) Positive inotropic effects of the endogenous Na+/K(+)-transporting ATPase inhibitor from the hypothalamus. Proc Natl Acad Sci U S A 86: 10080-10084.
33. Bao Y, Sun X, Yerong Y, Shuyuan L, Yang W, (2012) Blockers of sulfonylureas receptor 1 subunits may lead to cardiac protection against isoprenaline-induced injury in obese rats. Eur J Pharmacol 690: 142-148.
34. Sarazan RD, Kroehle JP, Main BW, (2012) Left ventricular pressure, contractility and dP/dt(max) in nonclinical drug safety assessment studies. J Pharmacol Toxicol Methods 66: 71-78.
35. Gao S, Oh YB, Park BM, Park WH, Kim SH, (2012) Urotensin II protects ischemic reperfusion injury of hearts through ROS and antioxidant pathway. Peptides 36: 199-205.
36. Zivkovic V, Jakovljevic V, Djordjevic D, Vuletic M, Barudzic N, et al. (2012) The effects of homocysteine-related compounds on cardiac contractility, coronary flow, and oxidative stress markers in isolated rat heart. Mol Cell Biochem 370: 59-67.
37. Collino M, Benetti E, Miglio G, Castiglia S, Rosa AC, et al. (2011) Peroxisome proliferator-activated receptor beta/delta agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. Free Radic Biol Med 50: 345-353.
38. Kapoor A, Shintani Y, Collino M, Osuchowski MF, Busch D, et al. (2010) Protective role of peroxisome proliferator-activated receptor-beta/delta in septic shock. Am J Respir Crit Care Med 182: 1506-1515.
39. Quintela AM, Jimenez R, Gomez-Guzman M, Zarzuelo MJ, Galindo P, et al. (2012) Activation of peroxisome proliferator-activated receptor-beta/-delta (PPARbeta/delta) prevents endothelial dysfunction in type 1 diabetic rats. Free Radic Biol Med 53: 730-741.
40. Marquardt R, (1979) [Effect of dopamine and metaproterenol on serum free fatty acids with regard to the induction of cardiac arrhythmia]. Med Welt 30: 707-708.
41. Angelakos ET, King MP, Millard RW, (1969) Regional distribution of catecholamines in the hearts of various species. Ann N Y Acad Sci 156: 219-240.
42. Beiser GD, Epstein SE, Goldstein RE, Stampfer M, Braunwald E, (1970) Comparison of the peak inotropic effects of a catecholamine and a digitalis glycoside in the intact canine heart. Circulation 42: 805-813.
43. Scriven AJ, Dollery CT, Murphy MB, Macquin I, Brown MJ, (1983) Blood pressure and plasma norepinephrine concentrations after endogenous norepinephrine release by tyramine. Clin Pharmacol Ther 33: 710-716.
44. Borthne K, Haga P, Langslet A, Lindberg H, Skomedal T, et al. (1995) Endogenous norepinephrine stimulates both alpha 1- and beta-adrenoceptors in myocardium from children with congenital heart defects. J Mol Cell Cardiol 27: 693-699.
45. Oh YJ, Lee JH, Kim JY, Song JW, Hong YW, et al. (2005) The haemodynamic effects of propranolol and atenolol medication on dobutamine infusion in patients with coronary artery obstructive disease. J Int Med Res 33: 329-336.
46. Schneyer CA, Yu JH, Jirakulsomchok D, (1985) Modification of dobutamine- and terbutaline-induced calcium and fluid secretion from rat salivary glands by atenolol and butoxamine. J Auton Nerv Syst 13: 275-285.
47. Coletta C, Galati A, Ricci R, Aspromonte N, Sestili A, et al. (1998) ECG changes during dobutamine stress test and spontaneous recovery of contractility in patients with myocardial infarction. G Ital Cardiol 28: 349-356.
48. McEntee K, Amory H, Pypendop B, Balligand M, Clercx C, et al. (1998) Effects of dobutamine on isovolumic and ejection phase indices of cardiac contractility in conscious healthy dogs. Res Vet Sci 64: 45-50.
49. Ohtsuki I, Morimoto S, (2008) Troponin: regulatory function and disorders. Biochem Biophys Res Commun 369: 62-73.
50. Metzger JM, Westfall MV, (2004) Covalent and noncovalent modification of thin filament action: the essential role of troponin in cardiac muscle regulation. Circ Res 94: 146-158.
51. Layland J, Solaro RJ, Shah AM, (2005) Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc Res 66: 12-21.
52. Bootman MD, Berridge MJ, (1995) The elemental principles of calcium signaling. Cell 83: 675-678.
53. Tate CA, Hyek MF, Taffet GE, (1991) The role of calcium in the energetics of contracting skeletal muscle. Sports Med 12: 208-217.
54. Liu X, Takeda N, Dhalla NS, (1996) Troponin I phosphorylation in heart homogenate from diabetic rat. Biochim Biophys Acta 1316: 78-84.
55. Messer AE, Jacques AM, Marston SB, (2007) Troponin phosphorylation and regulatory function in human heart muscle: dephosphorylation of Ser23/24 on troponin I could account for the contractile defect in end-stage heart failure. J Mol Cell Cardiol 42: 247-259.
56. Li L, Desantiago J, Chu G, Kranias EG, Bers DM, (2000) Phosphorylation of phospholamban and troponin I in beta-adrenergic-induced acceleration of cardiac relaxation. Am J Physiol Heart Circ Physiol 278: H769-779.
57. Pi Y, Kemnitz KR, Zhang D, Kranias EG, Walker JW, (2002) Phosphorylation of troponin I controls cardiac twitch dynamics: evidence from phosphorylation site mutants expressed on a troponin I-null background in mice. Circ Res 90: 649-656.